Short answer
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an 8-K current report with the SEC on September 25, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Senator Torricelli and Dr. Miller appointed as directors, expanding board oversight and healthcare-policy expertise.
CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Senator Torricelli and Dr. Miller appointed as directors, expanding board oversight and healthcare-policy expertise
- Dr. Miller brings Medicare, regulatory, clinical medicine and health-plan governance experience
- Each director receives pro rata 2026 board and committee retainers
- Each receives a pro-rated RSU award based on $200,000 annual value
- Standard indemnification agreements provide liability protection and expense advancement for both directors
Item EX-99.1 · Exhibit EX-99.1
- Two directors appointed effective immediately, filling vacancies and expanding the Board to nine directors
- Former Senator Torricelli joins the Audit Committee, adding federal healthcare policy and business oversight experience
- Dr. Brian Miller joins the Clinical Committee, bringing Medicare payment, regulatory, and frontline physician expertise
- Appointments strengthen oversight of Clover’s Medicare Advantage strategy, clinical technology, and policy exposure
- No transaction or financial obligation disclosed; investor impact centers on governance and execution credibility
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K filings
Get the next CLOV 8-K as it lands
Follow CLOV for push alerts, or ask the research agent what this filing means.